Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6553050 | 0.90 | DRD2 (0.42) | DRD2ADRA1DHTR1DSLC6A4ADRA1A | |
| SCHEMBL6552830 | 0.88 | — | — | |
| SCHEMBL6551561 | 0.87 | DRD2 (0.30) | DRD2ADRA1DHTR1DSLC6A4ADRA1A | |
| SCHEMBL6552901 | 0.80 | DRD2 (0.36) | DRD2ADRA1DHTR1DSLC6A4ADRA1A | |
| SCHEMBL6552858 | 0.75 | DAO (0.32) | — | |
| SCHEMBL6552783 | 0.70 | TAAR1 (0.33) | DRD2HTR1D | |
| SCHEMBL6809472 | 0.70 | DRD1 (0.43) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6551590 | 0.66 | TAAR1 (0.59) | DRD2 | |
| SCHEMBL6812077 | 0.66 | HTR1D (0.43) | DRD2HTR1DSLC6A4 | |
| SCHEMBL5097946 | 0.66 | HTR1D (0.43) | DRD2HTR1DSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | DRD2 70/4885ADRA1D 28/4885HTR1D 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.